# Arcus Biosciences

> Arcus Biosciences is a Hayward, California-based clinical-stage biopharmaceutical company that discovers and develops small molecules and antibodies for cancer and, increasingly, inflammatory and autoimmune diseases. Its model is built around owning drug-discovery capabilities, designing medicines that can work in rational combinations, and sharing development costs and future economics with large pharmaceutical partners. The current center of gravity is casdatifan, a HIF-2alpha inhibitor in Phase 3 development for clear-cell renal cell carcinoma, alongside the Phase 3 pancreatic-cancer candidate quemliclustat and an emerging inflammation portfolio.

- **Founded:** 2015
- **Headquarters:** Hayward, United States
- **Founders:** Terry Rosen (Co-founder and CEO), Juan Jaen (Co-founder and President)
- **Team size:** Approximately 630 employees; LinkedIn listed about 647 employees in 2026.
- **Products:** Casdatifan, Quemliclustat, AB102, Inflammation discovery portfolio, Domvanalimab and zimberelimab
- **Notable:** Advanced casdatifan and quemliclustat into registrational Phase 3 studies., Completed a $120 million initial public offering on the NYSE in March 2018 under ticker RCUS., Secured a 10-year strategic alliance with Gilead that included major upfront, equity and option payments.

## Products & services

- **Casdatifan** — Investigational oral HIF-2alpha inhibitor in Phase 3 development for clear-cell renal cell carcinoma, including the PEAK-1 combination study with cabozantinib.
- **Quemliclustat** — Investigational small-molecule CD73 inhibitor in the Phase 3 PRISM-1 study with chemotherapy for first-line metastatic pancreatic ductal adenocarcinoma.
- **AB102** — Investigational oral MRGPRX2 antagonist selected for development in atopic dermatitis and chronic spontaneous urticaria; clinical entry was planned for the third quarter of 2026.
- **Inflammation discovery portfolio** — Preclinical small-molecule programs against TNF, CCR6, STAT6 and CD40L, plus an anti-CD89 monoclonal antibody program.
- **Domvanalimab and zimberelimab** — Investigational Fc-silent anti-TIGIT and anti-PD-1 antibodies. The STAR-121 lung-cancer study was discontinued for futility in April 2026, while the broader programs are subject to partner and study decisions.

## Achievements

- Advanced casdatifan and quemliclustat into registrational Phase 3 studies.
- Completed a $120 million initial public offering on the NYSE in March 2018 under ticker RCUS.
- Secured a 10-year strategic alliance with Gilead that included major upfront, equity and option payments.
- Reported 45.2% confirmed overall response rate and 15.1-month median progression-free survival in the 100 mg casdatifan monotherapy cohort of ARC-20 as of January 30, 2026; these were early-stage, non-randomized data.
- Published translational ARC-20 research in Nature in July 2026 linking erythropoietin suppression, HIF-2alpha biology and clinical outcomes.
- Built internal small-molecule medicinal chemistry and antibody-discovery capabilities rather than organizing around a single founding asset.
- Named to Fortune Bay Area and biopharma workplace lists in multiple years, according to the company careers site.

## Latest updates

- **2026-07** — Arcus announced publication of ARC-20 translational research in Nature connecting casdatifan activity with HIF-2alpha biology and erythropoietin suppression.
- **2026-06** — Arcus and Bristol Myers Squibb agreed to add casdatifan combination arms with pumitamig to the ROSETTA RCC-208 kidney-cancer study.
- **2026-05** — First-quarter results showed $876 million in cash and investments, $17 million of revenue, and runway guidance into at least the second half of 2028.
- **2026-04** — Arcus discontinued Phase 3 STAR-121 and Phase 2 EDGE-Lung after a futility analysis found no overall-survival improvement for the domvanalimab regimen versus pembrolizumab plus chemotherapy.
- **2026-02** — Updated ARC-20 data showed a 45.2% confirmed response rate and 15.1-month median progression-free survival in the casdatifan 100 mg cohort.

## Links

- Website: https://arcusbio.com
- LinkedIn: https://www.linkedin.com/company/arcus-biosciences
- Twitter/X: https://twitter.com/arcusbio
- Facebook: https://www.facebook.com/arcusbiosciences/

---

Profile page: https://yespress.io/arcus-biosciences
Published by YesPress — https://yespress.io
Last updated: 2026-08-10